Jul. 4 at 3:12 PM
$ARDX Realistically, I'd dismiss valuations of
$10 bilion or more as far-fetched, and in my opinion, these are overly bullish projections. Remember, Big Pharma, just like Ardelyx, will be weighing the pros and cons. A
$10 B valuation alone requires the share price to reach roughly
$25 30-60 days befor transaction. And we're talking about a
$40 per share. That's a pipe dream. Impossible, in my opinion. This company might be worth that much in years to come and BP won;t wait for years for a transaction wgen their patents expire. A realistic takeover valuation, in my opinion is around
$20-25 per share, or
$5-6,5B. Nothing more. That would still be a huge success. And we could wake up to a
$3-3,5B transaction. That's reality. Xphozah was cut in the US, Ibsrela is a US-Only company. The rest of the predictions are in the distant future.
To get a
$20 valuation right now, we're talking about a pre-trade valuation of
$10-12 for 30-60 days. And we're looking at 5-6...
